💥𝐀𝐥𝐥𝐞𝐫𝐭💥

Acute angle-closure glaucoma (AACG) is a critical ophthalmic emergency that can lead to rapid vision loss if not promptly treated. Globally, approximately 𝟏𝟔 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 individuals are affected by angle-closure glaucoma, with nearly 𝟒 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 suffering from bilateral blindness due to this condition.
Projections indicate that by 2040, the number of people with primary angle-closure glaucoma (PACG) will rise to 𝐨𝐯𝐞𝐫 𝟑𝟐 𝐦𝐢𝐥𝐥𝐢𝐨𝐧, with a significant majority being of Asian descent. These statistics underscore the urgent need for early detection and intervention to prevent irreversible vision impairment associated with AACG.

🎉 Let 𝐂𝐏𝐂𝟏𝐇𝐍 helps you dominate this promising market with 𝐏𝐢𝐥𝐨𝐝𝐫𝐨𝐩:
🌟 Rapid action within 𝟏𝟎–𝟑𝟎 𝐦𝐢𝐧𝐮𝐭𝐞𝐬, lasting 𝟔–𝟖 𝐡𝐨𝐮𝐫𝐬
🌟 The first-line treatment of ACUTE ANGLE-CLOSURE GLAUCOMA.
🌟 Can be Applied after Phaco surgery
🌟 pHFast technology – helps adjust pH to the physiological level of the eye, enhancing penetration ability, reducing irritation.
🌟 BFS sterile technology – combined with a convenient dropper design.

📩 𝗖𝗢𝗡𝗧𝗔𝗖𝗧 𝗨𝗦 𝗡𝗢𝗪
𝗠𝐫𝐬. 𝐓𝐡𝐚𝐧𝐡 𝐗𝐮𝐚𝐧 (𝐒𝐭𝐞𝐥𝐥𝐚) – 𝗘𝘅𝗽𝗼𝗿𝘁 𝐃𝐢𝐫𝐞𝐜𝐭𝐨𝐫
𝑴𝒐𝒃𝒊𝒍𝒆/𝑾𝒉𝒂𝒕𝒔𝒂𝒑𝒑/𝑻𝒆𝒍𝒆𝒈𝒓𝒂𝒎/𝑽𝒊𝒃𝒆𝒓: +84 984 404 650
𝑬𝒎𝒂𝒊𝒍: thanhxuan.exp@cpc1hn.vn
𝑾𝒆𝒃𝒔𝒊𝒕𝒆: https://cpc1hn.com/

𝑯𝒂𝒏𝒐𝒊 𝑪𝑷𝑪1 𝑷𝒉𝒂𝒓𝒎𝒂𝒄𝒆𝒖𝒕𝒊𝒄𝒂𝒍 – 𝑫𝒊𝒇𝒇𝒆𝒓𝒆𝒏𝒕 𝒘𝒊𝒕𝒉 𝑻𝒆𝒄𝒉𝒏𝒐𝒍𝒐𝒈𝒚